ArticlePloS one2025
Survey of clot waveform analysis of normal activated partial thromboplastin time in patients with cirrhosis and sepsis at Le Van Thinh hospital.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to establish the correlation between activated partial thromboplastin time (aPTT) in seconds and ratio, first derivative peak (Max1), second derivative peak (Max2), second derivative minimum peak (Min2), and delta-OD of clot waveform analysis in patients diagnosed with cirrhosis, sepsis, and a control group. The study involved a series of cases using the Bayesian ANOVA model with Bayes factor (BF) estimated using the Markov Chain Monte Carlo sampling method with 2 chains. Each chain consisted of 10 000 repetitions and started 5 000 times to predict the variables aPTT (s), aPTT (ratio), Max1, Max2, Min2, and delta-OD respectively across the 3 study groups. The model used was variable ~ stage - 1. This analysis illustrates the adjustment of the posterior proportion for multiple testing by setting the prior probability of the initial hypothesis to 0.5 for all comparisons. There is insufficient evidence that aPTT (s), aPTT (ratio), and Min2 differ between the study groups (0 < BF < 3). There is compelling evidence for the Max1 value in both the sepsis group and the control group (BF10 = 44.042). Additionally, between the sepsis group and the cirrhosis group, there is substantial evidence for the Max1 value (BF10 = 5.842). Moreover, there is convincing evidence for the Max2 value in the sepsis group compared to the control group (BF10 = 38.782). There is almost confirmatory evidence that the delta-OD value in the sepsis group is higher than that in the control group (BF10 = 1251.781). Finally, there is convincing evidence that the sepsis group has a higher delta-OD value than the cirrhosis group (BF10 = 35.555). The Max1, Max2, and delta-OD indices effectively reflect coagulation disorders in patients with cirrhosis and sepsis, even when the aPTT test results are within normal limits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.